Dissecting the clinical trial surge in H1 2025
Amidst significant shifts in the pharmaceutical industry, the number of clinical trials has surged over the first half of 2025.…
All articles by Manasi Vaidya
Manasi Vaidya
@manasivaidya22
Manasi Vaidya is an editor for GlobalData Insights where she covers the healthcare space. She writes and edits features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science.
-
-
FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use
US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability…
-
Placing the patient at the centre of the drug development paradigm
As advocacy efforts bolster the need for patient-focused drug development, amidst regulatory encouragement, the value of listening to patients is…
-
How to integrate patients into clinical research with cohesive strategies
As patient voices get amplified across platforms, finding effective ways to further enhance participation and let patient-driven inputs drive clinical…
-
Trump picks vaccine sceptic RFK Jr to lead HHS in new administration
President-elect Donald Trump has appointed Robert F Kennedy Jr, popularly known as RFK Jr, as the secretary of the premier…
-
How logistics shape the success of rare disease trials
As any seasoned expert in the clinical trials field would affirm, it is not enough to have an innovative therapeutic…
-
Navigating clinical trial operations in the era of collaboration
Running a successful clinical trial requires a combination of sector expertise, an eye towards emerging technologies and efforts to consider…
-
How to connect patients with rare diseases to clinical trials
Rare disease clinical research is no longer an afterthought for pharmaceutical companies with rapid approvals and increased investment in this…
-
Rare disease drug development needs regulatory incentives to grow in 2024
Last year, over half of the novel drugs approved by the US Food and Drug Administration (FDA) were orphan drugs,…
-
Signal- HHS-Regeneron Covid-19 deal includes list price clause for affordability
Regeneron Pharmaceuticals will sell potential Covid-19 prophylactic antibody at an internationally comparable price in the US to make it more…